[Anti-VEGF therapy of exudative AMD: Prognostic factors for therapy success]
- PMID: 20535478
- DOI: 10.1007/s00347-010-2210-z
[Anti-VEGF therapy of exudative AMD: Prognostic factors for therapy success]
Abstract
Background: The aim of the study was to evaluate possible prognostic and predictive factors (morphologic and functional) of the individual visual gain/decline after anti-VEGF therapy of exudative AMD.
Patients/methods: Best corrected visual acuity (VA), microperimetric sensitivity (RS), retinal thickness (RT) and autofluorescence pattern (AF) were documented in 128 patients with exudative AMD.
Results: Eyes with classic choroidal neovascularization (CNV) had the best visual gain but still remained at a lower level. Eyes which initially had the lowest VA had the largest gain and those with good initial VA could maintain this level. There was no correlation between RT and visual outcome. Eyes with initially normal AF had a significantly greater visual gain.
Conclusions: The type of CNV, initial VA, RS and the initial RT were only of limited usefulness, while the initial foveal AF was most important predictive factor. This may indicate that preexisting changes and irreversible damage in the outer retina and/or retinal pigment epithelium are responsible for the resulting VA after therapy.
Similar articles
-
[Retrospective investigation of anti-VEGF treatment reality and effectiveness in patients with neovascular age-related macular degeneration (AMD) in Germany: treatment reality of ranibizumab for neovascular AMD in Germany].Ophthalmologe. 2015 Mar;112(3):246-54. doi: 10.1007/s00347-014-3217-7. Ophthalmologe. 2015. PMID: 25668709 German.
-
Foveal RPE autofluorescence as a prognostic factor for anti-VEGF therapy in exudative AMD.Graefes Arch Clin Exp Ophthalmol. 2008 Sep;246(9):1229-34. doi: 10.1007/s00417-008-0854-z. Epub 2008 May 29. Graefes Arch Clin Exp Ophthalmol. 2008. PMID: 18509668
-
Fellow Eye Comparisons for 7-Year Outcomes in Ranibizumab-Treated AMD Subjects from ANCHOR, MARINA, and HORIZON (SEVEN-UP Study).Ophthalmology. 2016 Jun;123(6):1269-77. doi: 10.1016/j.ophtha.2016.01.033. Epub 2016 Mar 18. Ophthalmology. 2016. PMID: 26996339
-
Defining response to anti-VEGF therapies in neovascular AMD.Eye (Lond). 2015 Jun;29(6):721-31. doi: 10.1038/eye.2015.48. Epub 2015 Apr 17. Eye (Lond). 2015. PMID: 25882328 Free PMC article. Review.
-
Anti-VEGF therapies and blood pressure: more than meets the eye.Curr Hypertens Rep. 2010 Feb;12(1):33-8. doi: 10.1007/s11906-009-0082-x. Curr Hypertens Rep. 2010. PMID: 20425156 Review.
Cited by
-
[Visual acuity in anti-VEGF therapy for AMD : Can specific characteristics in the SD-OCT help?].Ophthalmologe. 2017 Jan;114(1):49-56. doi: 10.1007/s00347-016-0308-7. Ophthalmologe. 2017. PMID: 27364636 German.
-
Inflammatory cytokines in aqueous humor of patients with choroidal neovascularization.Mol Vis. 2012;18:574-80. Epub 2012 Mar 2. Mol Vis. 2012. PMID: 22419849 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical